Practical and effective cardiac repair to prevent and reverse chronic heart failure
The Challenge: Cardiac muscle damage frequently leads to advanced Heart Failure (HF), the inability of the heart to pump sufficient blood to and from the rest of the body. HF is progressive and debilitating as patients experience a significant decline in physical and cognitive function with increased hospitalizations. Drugs, surgery, and devices are insufficient to reverse the decline and the prognosis is poor as 50% of patients die within 5 years of diagnosis. In the US, the prevalence of HF lies well above 5 million patients and will continue growing. It represents the most common cause of hospitalizations in adults over 65 years of age. The direct cost to treat HF lies above $35 billion per year.
The Solution: The MateraCor system combines two products to stop and reverse the progression of HF. The system’s first component is an implantable intramyocardial hydrogel that restores adequate heart function and improves clinical symptoms by reducing heart muscle stress and reshaping the left ventricle. Its safety and efficacy have been shown in randomized clinical trials using a surgical (open chest) delivery. To prevent that surgery, the system’s second component has now been developed and validated in large animal models. It is an intramyocardial delivery catheter that injects hydrogels and other payloads to the heart muscle using common interventional techniques and percutaneous endocardial access. The catheter is unique in its ability to transport fully gelled materials with various safety features. Requiring a single one-time procedure, the MateraCor system does not interfere with other drug or device therapies and may in fact be synergistic. In the future, the two system components may also be used as a platform to deliver regenerative biologics and small molecules.